Download PDF
Semin Respir Crit Care Med 2016; 37(04): 572-577
DOI: 10.1055/s-0036-1584796
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Middle East Respiratory Syndrome Virus Pathogenesis

Sunit K. Singh
1   Molecular Biology Unit, Institute of Medical Sciences, Banaras Hindu University (BHU), Varanasi, Uttar Pradesh, India
› Author Affiliations
Further Information

Publication History

Publication Date:
03 August 2016 (online)

   Permissions and Reprints

Abstract

Coronaviruses (CoVs) are enveloped RNA viruses that infect birds, mammals, and humans. Infections caused by human coronaviruses (hCoVs) are mostly associated with the respiratory, enteric, and nervous systems. The hCoVs only occasionally induce lower respiratory tract disease, including bronchitis, bronchiolitis, and pneumonia. In 2002 to 2003, a global outbreak of severe acute respiratory syndrome (SARS) was the seminal detection of a novel CoV (SARS-CoV). A decade later (June 2012), another novel CoV was implicated as the cause of Middle East respiratory syndrome (MERS) in Saudi Arabia. Although bats might serve as a reservoir of MERS-CoV, it is unlikely that they are the direct source for most human cases. Severe lines of evidence suggest that dromedary camels have been the major cause of transmission to humans. The emergence of MERS-CoV has triggered serious concerns about the potential for a widespread outbreak. All MERS cases were linked directly or indirectly to the Middle East region including Saudi Arabia, Jordan, Qatar, Oman, Kuwait, and UAE. MERS cases have also been reported in the later phases in the United Kingdom, France, Germany, Italy, Spain, and Tunisia. Most of these MERS cases were linked with the Middle East. The high mortality rates in family-based and hospital-based outbreaks were reported among patients with comorbidities such as diabetes and renal failure. MERS-CoV causes an acute, highly lethal pneumonia and renal dysfunction. The major complications reported in fatal cases are hyperkalemia with associated ventricular tachycardia, disseminated intravascular coagulation, pericarditis, and multiorgan failure. The case-fatality rate seems to be higher for MERS-CoV (around 30%) than for SARS-CoV (9.6%). The combination regimen of type 1 interferon + lopinavir/ritonavir is considered as the first-line therapy for MERS. Antiviral treatment is generally recommended for 10 to 14 days in patients with MERS-CoV infection. Convalescent plasma therapy has shown some efficacy among patients refractory to antiviral drugs if administered within 2 weeks of the onset of the disease.

Keywords

coronavirus - SARS-CoV - MERS-CoV
 

  • References

  • 1 Woo PC, Lau SK, Chu CM , et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 2005; 79 (2) 884-895
    CrossrefPubMedGoogle Scholar
  • 2 Durai P, Batool M, Shah M, Choi S. Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control. Exp Mol Med 2015; 47: e181
    CrossrefPubMedGoogle Scholar
  • 3 Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 2005; 69 (4) 635-664
    CrossrefPubMedGoogle Scholar
  • 4 Fouchier RA, Hartwig NG, Bestebroer TM , et al. A previously undescribed coronavirus associated with respiratory disease in humans. Proc Natl Acad Sci U S A 2004; 101 (16) 6212-6216
    CrossrefPubMedGoogle Scholar
  • 5 van den Brand JM, Smits SL, Haagmans BL. Pathogenesis of Middle East respiratory syndrome coronavirus. J Pathol 2015; 235 (2) 175-184
    CrossrefPubMedGoogle Scholar
  • 6 Gaunt ER, Hardie A, Claas EC, Simmonds P, Templeton KE. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol 2010; 48 (8) 2940-2947
    CrossrefPubMedGoogle Scholar
  • 7 Álvarez E, Donado-Campos J, Morilla F. New coronavirus outbreak. Lessons learned from the severe acute respiratory syndrome epidemic. Epidemiol Infect 2015; 143 (13) 2882-2893
    CrossrefPubMedGoogle Scholar
  • 8 Sharif-Yakan A, Kanj SS. Emergence of MERS-CoV in the Middle East: origins, transmission, treatment, and perspectives. PLoS Pathog 2014; 10 (12) e1004457
    CrossrefPubMedGoogle Scholar
  • 9 Woo PC, Lau SK, Li KS, Tsang AK, Yuen KY. Genetic relatedness of the novel human group C betacoronavirus to Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5. Emerg Microbes Infect 2012; 1 (11) e35
    CrossrefPubMedGoogle Scholar
  • 10 de Groot RJ, Baker SC, Baric RS , et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol 2013; 87 (14) 7790-7792
    CrossrefPubMedGoogle Scholar
  • 11 Woo PC, Lau SK, Li KS , et al. Molecular diversity of coronaviruses in bats. Virology 2006; 351 (1) 180-187
    CrossrefPubMedGoogle Scholar
  • 12 Reusken CB, Lina PH, Pielaat A , et al. Circulation of group 2 coronaviruses in a bat species common to urban areas in Western Europe. Vector Borne Zoonotic Dis 2010; 10 (8) 785-791
    CrossrefPubMedGoogle Scholar
  • 13 van Boheemen S, de Graaf M, Lauber C , et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 2012; 3 (6) 473-512
    PubMedGoogle Scholar
  • 14 Ithete NL, Stoffberg S, Corman VM , et al. Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa. Emerg Infect Dis 2013; 19 (10) 1697-1699
    CrossrefPubMedGoogle Scholar
  • 15 Haagmans BL, Al Dhahiry SH, Reusken CB , et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis 2014; 14 (2) 140-145
    CrossrefPubMedGoogle Scholar
  • 16 Banik GR, Khandaker G, Rashid H. Middle East respiratory syndrome coronavirus “MERS-CoV”: current knowledge gaps. Paediatr Respir Rev 2015; 16 (3) 197-202
    PubMedGoogle Scholar
  • 17 Reusken CB, Haagmans BL, Müller MA , et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 2013; 13 (10) 859-866
    CrossrefPubMedGoogle Scholar
  • 18 Perera RA, Wang P, Gomaa MR , et al. Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill 2013; 18 (36) 20574
    CrossrefPubMedGoogle Scholar
  • 19 van Doremalen N, Bushmaker T, Karesh WB, Munster VJ. Stability of Middle East respiratory syndrome coronavirus in milk. Emerg Infect Dis 2014; 20 (7) 1263-1264
    CrossrefPubMedGoogle Scholar
  • 20 Alagaili AN, Briese T, Karesh WB, Daszak P, Lipkin WI. Reply to “Concerns about misinterpretation of recent scientific data implicating dromedary camels in epidemiology of Middle East respiratory syndrome (MERS)”. MBio 2014; 5 (4) e01482-e14
    PubMedGoogle Scholar
  • 21 Azhar EI, El-Kafrawy SA, Farraj SA , et al. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 2014; 370 (26) 2499-2505
    CrossrefPubMedGoogle Scholar
  • 22 Vijgen L, Keyaerts E, Lemey P , et al. Evolutionary history of the closely related group 2 coronaviruses: porcine hemagglutinating encephalomyelitis virus, bovine coronavirus, and human coronavirus OC43. J Virol 2006; 80 (14) 7270-7274
    CrossrefPubMedGoogle Scholar
  • 23 de Sousa R, Reusken C, Koopmans M. MERS coronavirus: data gaps for laboratory preparedness. J Clin Virol 2014; 59 (1) 4-11
    CrossrefPubMedGoogle Scholar
  • 24 Assiri A, McGeer A, Perl TM , et al; KSA MERS-CoV Investigation Team. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013; 369 (5) 407-416
    CrossrefPubMedGoogle Scholar
  • 25 Raj VS, Osterhaus AD, Fouchier RA, Haagmans BL. MERS: emergence of a novel human coronavirus. Curr Opin Virol 2014; 5: 58-62
    CrossrefPubMedGoogle Scholar
  • 26 Arabi YM, Arifi AA, Balkhy HH , et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 2014; 160 (6) 389-397
    PubMedGoogle Scholar
  • 27 Assiri A, Al-Tawfiq JA, Al-Rabeeah AA , et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13 (9) 752-761
    CrossrefPubMedGoogle Scholar
  • 28 Zhang N, Jiang S, Du L. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines 2014; 13 (6) 761-774
    CrossrefPubMedGoogle Scholar
  • 29 Tomar S, Johnston ML, St John SE , et al. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS. J Biol Chem 2015; 290 (32) 19403-19422
    CrossrefPubMedGoogle Scholar
  • 30 Bailey-Elkin BA, Knaap RC, Johnson GG , et al. Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression. J Biol Chem 2014; 289 (50) 34667-34682
    CrossrefPubMedGoogle Scholar
  • 31 Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 2009; 7 (6) 439-450
    CrossrefPubMedGoogle Scholar
  • 32 Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015; 386 (9997) 995-1007
    CrossrefPubMedGoogle Scholar
  • 33 Smith EC, Blanc H, Surdel MC, Vignuzzi M, Denison MR. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog 2013; 9 (8) e1003565
    CrossrefPubMedGoogle Scholar
  • 34 Kindler E, Jónsdóttir HR, Muth D , et al. Efficient replication of the novel human betacoronavirus EMC on primary human epithelium highlights its zoonotic potential. MBio 2013; 4 (1) e00611-e00612
    PubMedGoogle Scholar
  • 35 Zielecki F, Weber M, Eickmann M , et al. Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus. J Virol 2013; 87 (9) 5300-5304
    CrossrefPubMedGoogle Scholar
  • 36 Raj VS, Mou H, Smits SL , et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495 (7440) 251-254
    CrossrefPubMedGoogle Scholar
  • 37 Li W, Moore MJ, Vasilieva N , et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426 (6965) 450-454
    Google Scholar
  • 38 Perlman S. The Middle East respiratory syndrome—how worried should we be?. MBio 2013; 4 (4) 531-613
    PubMedGoogle Scholar
  • 39 Hocke AC, Becher A, Knepper J , et al. Emerging human middle East respiratory syndrome coronavirus causes widespread infection and alveolar damage in human lungs. Am J Respir Crit Care Med 2013; 188 (7) 882-886
    CrossrefPubMedGoogle Scholar
  • 40 de Wilde AH, Raj VS, Oudshoorn D , et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment. J Gen Virol 2013; 94 (Pt 8) 1749-1760
    CrossrefPubMedGoogle Scholar
  • 41 Delmas B, Gelfi J, L'Haridon R , et al. Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus TGEV. Nature 1992; 357 (6377) 417-420
    CrossrefPubMedGoogle Scholar
  • 42 Raj VS, Smits SL, Provacia LB , et al. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus. J Virol 2014; 88 (3) 1834-1838
    CrossrefPubMedGoogle Scholar
  • 43 Jiang S, Lu L, Du L, Debnath AK. A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. J Infect 2013; 66 (5) 464-466
    CrossrefPubMedGoogle Scholar
  • 44 Imai Y, Kuba K, Ohto-Nakanishi T, Penninger JM. Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ J 2010; 74 (3) 405-410
    CrossrefPubMedGoogle Scholar
  • 45 Herlihy SE, Pilling D, Maharjan AS, Gomer RH. Dipeptidyl peptidase IV is a human and murine neutrophil chemorepellent. J Immunol 2013; 190 (12) 6468-6477
    CrossrefPubMedGoogle Scholar
  • 46 Gierer S, Bertram S, Kaup F , et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol 2013; 87 (10) 5502-5511
    CrossrefPubMedGoogle Scholar
  • 47 Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40 (3) 209-294
    CrossrefPubMedGoogle Scholar
  • 48 Cowling BJ, Park M, Fang VJ, Wu P, Leung GM, Wu JT. Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015. Euro Surveill 2015; 20 (25) 7-13
    PubMedGoogle Scholar
  • 49 Chan RW, Chan MC, Agnihothram S , et al. Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J Virol 2013; 87 (12) 6604-6614
    CrossrefPubMedGoogle Scholar
  • 50 Zhou J, Chu H, Li C , et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis 2014; 209 (9) 1331-1342
    CrossrefPubMedGoogle Scholar
  • 51 Lau SK, Lau CC, Chan KH , et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol 2013; 94 (Pt 12) 2679-2690
    CrossrefPubMedGoogle Scholar
  • 52 Cameron MJ, Ran L, Xu L , et al; Canadian SARS Research Network. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol 2007; 81 (16) 8692-8706
    CrossrefPubMedGoogle Scholar
  • 53 Al-Tawfiq JA, Hinedi K, Ghandour J , et al. Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients. Clin Infect Dis 2014; 59 (2) 160-165
    CrossrefPubMedGoogle Scholar
  • 54 Memish ZA, Al-Tawfiq JA, Assiri A , et al. Middle East respiratory syndrome coronavirus disease in children. Pediatr Infect Dis J 2014; 33 (9) 904-906
    CrossrefPubMedGoogle Scholar
  • 55 Guery B, Poissy J, el Mansouf L , et al; MERS-CoV Study Group. Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission. Lancet 2013; 381 (9885) 2265-2272
    CrossrefPubMedGoogle Scholar
  • 56 Drosten C, Seilmaier M, Corman VM , et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 2013; 13 (9) 745-751
    CrossrefPubMedGoogle Scholar
  • 57 Memish ZA, Assiri A, Almasri M , et al. Prevalence of MERS-CoV nasal carriage and compliance with the Saudi health recommendations among pilgrims attending the 2013 Hajj. J Infect Dis 2014; 210 (7) 1067-1072
    CrossrefPubMedGoogle Scholar
  • 58 Al-Abdallat MM, Payne DC, Alqasrawi S , et al; Jordan MERS-CoV Investigation Team. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis 2014; 59 (9) 1225-1233
    CrossrefPubMedGoogle Scholar
  • 59 Ajlan AM, Ahyad RA, Jamjoom LG, Alharthy A, Madani TA. Middle East respiratory syndrome coronavirus (MERS-CoV) infection: chest CT findings. AJR Am J Roentgenol 2014; 203 (4) 782-787
    CrossrefPubMedGoogle Scholar
  • 60 Nicholls JM, Poon LL, Lee KC , et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003; 361 (9371) 1773-1778
    CrossrefPubMedGoogle Scholar
  • 61 Tse GM, To KF, Chan PK , et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol 2004; 57 (3) 260-265
    CrossrefPubMedGoogle Scholar
  • 62 Josset L, Menachery VD, Gralinski LE , et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. MBio 2013; 4 (3) e00165-e13
    PubMedGoogle Scholar
  • 63 Faure E, Poissy J, Goffard A , et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?. PLoS ONE 2014; 9 (2) e88716
    CrossrefPubMedGoogle Scholar
  • 64 Meyer B, Drosten C, Müller MA. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus Res 2014; 194: 175-183
    CrossrefPubMedGoogle Scholar
  • 65 Spanakis N, Tsiodras S, Haagmans BL , et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents 2014; 44 (6) 528-532
    CrossrefPubMedGoogle Scholar
  • 66 Gossner C, Danielson N, Gervelmeyer A , et al. Human-dromedary camel interactions and the risk of acquiring zoonotic Middle East respiratory syndrome coronavirus infection. Zoonoses Public Health 2016; 63 (1) 1-9
    CrossrefPubMedGoogle Scholar
  • 67 Shirato K, Yano T, Senba S , et al. Detection of Middle East respiratory syndrome coronavirus using reverse transcription loop-mediated isothermal amplification (RT-LAMP). Virol J 2014; 11: 139
    CrossrefPubMedGoogle Scholar
  • 68 Du L, Zhao G, Kou Z , et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 2013; 87 (17) 9939-9942
    CrossrefPubMedGoogle Scholar
  • 69 Raj VS, Lamers MM, Smits SL , et al. Identification of protein receptors for coronaviruses by mass spectrometry. Methods Mol Biol 2015; 1282: 165-182
    PubMedGoogle Scholar
  • 70 Memish ZA, Al-Tawfiq JA, Makhdoom HQ , et al. Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome. J Infect Dis 2014; 210 (10) 1590-1594
    CrossrefPubMedGoogle Scholar
  • 71 Chong YP, Song JY, Seo YB, Choi JP, Shin HS ; Rapid Response Team. Antiviral treatment guidelines for Middle East respiratory syndrome. Infect Chemother 2015; 47 (3) 212-222
    CrossrefPubMedGoogle Scholar
  • 72 Chan JF, Yao Y, Yeung ML , et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 2015; 212 (12) 1904-1913
    CrossrefPubMedGoogle Scholar
  • 73 Gara N, Ghany MG. What the infectious disease physician needs to know about pegylated interferon and ribavirin. Clin Infect Dis 2013; 56 (11) 1629-1636
    CrossrefPubMedGoogle Scholar
  • 74 Mair-Jenkins J, Saavedra-Campos M, Baillie JK , et al; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211 (1) 80-90
    CrossrefPubMedGoogle Scholar
  • 75 Hui DS, Memish ZA, Zumla A. Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Curr Opin Pulm Med 2014; 20 (3) 233-241
    PubMedGoogle Scholar